You searched for "floaters"
Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO
This paper is an analysis of data extracted from 13 eligible studies in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), collected from systematic literature search of MEDLINE, Embase, and Cochrane...Certifying patients as visually impaired: the start of a journey
In March 2017 there were 290,475 people registered as either visually impaired or severely visually impaired in the UK [1]. Patients registered as sight impaired benefit from financial support as well as practical help. Practical help is provided by social...Matt Stringer, RNIB’s Chief Executive Officer commented on the fifth anniversary of start of the Covid-19 pandemic
The UK was woefully ill-prepared for the Covid-19 pandemic, and indeed any type of pandemic, with regards to the rights and needs of blind and partially sighted people. This anniversary still demonstrates that critical lessons need to be learned to...Matt Stringer, RNIB’s Chief Executive Officer commented on the fifth anniversary of start of the Covid-19 pandemic (1)
“The UK was woefully ill-prepared for the Covid-19 pandemic, and indeed any type of pandemic, with regards to the rights and needs of blind and partially sighted people. This anniversary still demonstrates that critical lessons need to be learned to...
Outcomes of ‘treat and extend’ for neovascular AMD
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...
